Publication year: 2011
Source: European Journal of Cancer, Available online 15 November 2011
Gianfranco A. Pesce, Dirk Klingbiel, Karin Ribi, Abderahim Zouhair, Roger von Moos, ...
PurposePatients with brain metastases (BM) rarely survive longer than 6 months and are commonly excluded from clinical trials. We explored two combined modality regimens with novel agents with single agent activity and radiosensitizing properties.Patients and methodsIn this randomised phase II trial patients with BM from NSCLC were randomly assigned to 30 Gy WBRT with either concomitant gefitinib (GFT) 250 mg/day continuously or temozolomide (TMZ) 75 mg/mfor 21/28 days. The primary end-point was overall survival, with quality of life and cognitive function as secondary end-points.ResultsWe enrolled 59 patients (GFT 16, TMZ 43), and 56 patients have died, mainly (80%) from disease progression. Four patients succumbed complications of the disease or corticosteroids (intestinal perforation (2), CNS haemorrhage and pulmonary emboli). Median overall survival in the gefitinib arm was 6.3 months (95% CI 2.1–14.6), and 4.9 months (95% CI 2.3–5.6) in TMZ treated patients. Fatigue was the main complaint.ConclusionsNo relevant toxicity with those therapeutic regimens was observed. Fatal outcome in three patients may have been related to corticosteroids. Cognitive function improved during treatment. However, median overall survival for all patients was only 4.9 months (95% CI 2.3–5.7) and 1-year survival 25.4% (95% CI 15.4–37.0%).
No comments:
Post a Comment